Sign In

Friday, March 16, 2018 - 8:00 am to Saturday, March 17, 2018 - 12:45 pm
Add to Calendar

Emerging Trends Conference: Cholangiopathies: The Dawn of Curative Treatments?

Course Description/Need Statement

Thiss conference will review the most recent advances in genetics, pathogenesis and treatment opportunities of cholangiopathies, with emphasis on facilitating the development of new research collaboration and clinical trials to improve the outcome of children and adults with diseases of the biliary tree. Future research directions, including biomarker development and emerging therapeutic possibilities will also be discussed in depth.

Program Chairs

  • Maria Strazzabosco, MD, PhD, FAASLD
  • Christopher L. Bowlus, MD, FAASLD


  • Crystal Gateway Marriott
    Arlington, VA

Course Syllabus

  • The course agenda for this 2018 conference will be available in July 2017

Continuing Education

  • CME – 11 AMA PRA Category 1 Credits™
  • ABIM MOC - 11 Hours


Session I: Targeting Bile Acids and Bile Secretion

Friday, March 16

Moderators: Cynthia Levy, MD, FAASLD and Michael H. Trauner, MD, FAASLD

  • 7am
  • 8–8:15 am
    Welcome and Course Objectives
    Christopher L. Bowlus, MD, FAASLD 
  • 8:15–8:45 am
    Unmet Needs in Cholangiopathies
    Mario Strazzabosco, MD, PhD, FAASLD 
  • 8:45–9:05 am
    Bile Acids in Health and Disease and their Potential Targets for Therapies
    Michael H. Trauner, MD, FAASLD 
  • 9:05–9:25 am
    Bile Acids Clinical Treatments 
    Elizabeth J. Carey, MD, FAASLD
  • 9:25–9:55 am
    Panel Discussion 
  • 9:55–10:15 am

Session II: Targeting Inflammation

Friday, March 16

Moderators: David H. Adams, MD and Jorge A. Bezerra, MD, FAASLD

  • 10:15–10:35 am
    Immune Response and Inflammation in Cholangiopathies and Cholestatic Liver Diseases 
    David H. Adams, MD 
  • 10:35–10:55 am
    Autoinflammation in Congenital Hepatic Fibrosis 
    Carlo Spirli, PhD 
  • 10:55–11:15 am 
    Immuno-modulatory Strategies for Cholangiopathies
    Marlyn J. Mayo, MD, FAASLD
  • 11:15–11:45 am
    Panel Discussion
  • 11:45 am–1:15 pm
    Lunch and Poster Session

Session III: Targeting Biliary Fibrosis

Friday, March 16

Moderators: Massimo Pinzani, PhD, FAASLD and Rebecca G. Wells, MD 

  • 1:15–1:35 pm
    Cross-Talk Epithelial-Mesenchymal Cells in Biliary Fibrosis
    Rebecca G. Wells, MD 
  • 1:35–1:55 pm
    Targeting Fibrosis in Cholangiopathies
    Massimo Pinzani, PhD, FAASLD 
  • 1:55–2:15 pm
    Targeting Biliary Fibrosis and Inflammation in Biliary Atresia
    Jorge A. Bezerra, MD, FAASLD 
  • 2:15–2:35 pm
    Targeting Morphogens 
    Satdarshan (Paul) Singh Monga, MD, FAASLD 
  • 2:35–2:55 pm
    Panel Discussion
  • 2:55–3:15 pm

Session IV: Nuclear Receptors and Cholangiopathies

Friday, March 16

Moderators: Saul J. Karpen, MD, PhD, FAASLD and Olivier Barbier, PhD

  • 3:15–3:35 pm
    Nuclear Receptors and Cholangiopathies
    |Saul J. Karpen, MD, PhD, FAASLD 
  • 3:35–3:55 pm
    Fibrates, PPARs and Bile Acids Metabolism
    Olivier Barbier, PhD 
  • 3:55–4:15 pm
    Clinical Experience with Fibrates and Other PPARs Agonists
    Cynthia Levy, MD, FAASLD 
  • 4:15–4:35 pm
    Panel Discussion

Session V: Abstracts Presentation

Saturday, March 17

Moderators: Carlo Spirli, PhD

  • 7am
  • 8– 8:10 am
    Announcement of Poster Awards
  • 8:10–8:25 am
    Oral Presentation #1
  • 8:25–8:40 am
    Oral Presentation#2

Session VI: Genetic Cholangiopathies and Personalized Medicine

Saturday, March 17

Moderators: Keith D. Lindor, MD, FAASLD and Mario Strazzabosco, MD, PhD, FAASLD

  • 8:40–9 am
    Translational Advances in Cystic Fibrosis Cholangiopathy
    Romina Fiorotto, PhD 
  • 9– 9:20 am 
    Translational Advances in Polycystic Liver Diseases
    Nicholas F. LaRusso, MD, FAASLD 
  • 9:20– 9:40 am
    Special Populations and Cholangiopathies
    Marina G. Silveira, MD
  • 9:40–10 am
    Panel Discussion
  • 10–10:20 am


Session VII: Moving Therapeutics to the Clinic

Saturday, March 17

Moderators: Christopher L. Bowlus, MD, FAASLD and Cyriel Ponsioen, MD, PhD

  • 10:20–10:40 am
    Development of Surrogate Markers and Post-Approval Validation in PBC
    Marco Carbone, MD 
  • 10:40–11 am
    Bio-Markers of Disease Progression in PSC 
    Cyriel Ponsioen, MD PhD
  • 11:00–11:20 am
    Patient Reported Outcomes in PSC and PBC
    Donna M. Evon, PhD 
  • 11:20–11:40 am
    Pathways for Regulatory Approval of New Therapies for Cholestatic Liver Diseases
    Lara L Dimick-Santos, MD 
  • 11:40 am–Noon
    Clinical Trial Design for PBC in the Era of UDCA and OCA
    Keith D. Lindor, MD, FAASLD 
  • Noon–12:20 pm
    The Patient Perspective
    Ricky Safer 
  • 12:20–12.40 pm
    Panel Discussion
  • 12:40–1:00 pm
    Conference Summary and Wrap-Up 
  • Mario Strazzabosco, MD, PhD, FAASLD
  • 1:00 pm